Reprogramming Immunity: How CCR5 Blockade Could Redefine Cancer Therapy

Rx for Biotech
14/10/2025 29 min
Reprogramming Immunity: How CCR5 Blockade Could Redefine Cancer Therapy

Listen "Reprogramming Immunity: How CCR5 Blockade Could Redefine Cancer Therapy"

Descargar episodio Ver en sitio original

Episode Synopsis

In this podcast episode, Dr. Jay Lalezari, CEO of CytoDyn Therapeutics, discusses the company's progress in developing a novel immunotherapy that targets the CCR5 receptor, one of the master immune cell regulators. Jay reviews some of the early clinical data with leronlimab, a first-in-class investigational monocolonal antibody that targets the CCR5 receptor and is being studied in metasatic triple-negative breast cancer and colorectal cancer.

More episodes of the podcast Rx for Biotech

Restoring Breath: Biologic Innovation for the Most Vulenerable Patients 28/10/2025
The Alpha Edge: Perspective Therapeutics on the Future of Theranostics and Radiopharmaceutical Therapies 09/09/2025
Harnessing the Immune System: PDS Biotech’s NextGen Approach to Cancer Treatment 21/08/2025
How Nonacus is Changing Cancer Detection with CEO, Jeff Bousfield 05/08/2025
Hope in Hard Places: A Potential New Option for Patients with Pancreatic Cancer 24/07/2025
How Mesenchymal Stem Cells Are Shaping the Future of Medicine with Dr. Kilian Kelly 03/06/2025
Patient Perspective with CAR-T Cell Therapy Advocate, Brad Watt 08/05/2025
How AI is Transforming Job Search and Recruiting in Life Sciences and Technology 24/04/2025
From Nigeria to the USA: Gene Therapy Journey with Sickle Cell Warrior, Jimi Olaghere 24/03/2025
The Promise of Dendritic Cell Vaccines with Diakonos Oncology President and COO Jay Hartenbach 02/03/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA